Igor Sychev

Dr. Igor Sychev


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2025 in Messenger of ANESTHESIOLOGY AND RESUSCITATION
Verified
Journal Article
Open access
PDF file
VBV. B. Beloborodov
V. B. Beloborodov
OGO. V. Goloshchapov
O. V. Goloshchapov
VGV. G. Gusarov
V. G. Gusarov
ADA. V. Dekhnich
A. V. Dekhnich
MZM. N. Zamyatin
M. N. Zamyatin
SYS. V. Yakovlev
S. V. Yakovlev
Strains of microorganisms characterized by resistance to antimicrobial drugs used in medical organizations continue to spread in most regions of the world, including Russia. This naturally affects both the effectiveness of antimicrobial therapy and the tactics of its use not only in adults but also in children. The coronavirus pandemic has highlighted the growing problems with the treatment of invasive mycoses, the selection of dosage of antibacterial agents when using sorption and dialysis therapy methods. In combination with the registration of new antibacterial drugs ABSTRACT in Russia, this necessitated the need to make adjustments to the Methodological recommendations “Diagnostics and Antimicrobial Therapy of Infections Caused by Polyresistant Strains of Microorganisms” (2nd edition), prepared by a group of leading Russian experts in 2022 [1]. The presented version was approved in December 2024 at a joint meeting of representatives of public organizations: the Russian Association of Anesthesiologists-Intensivists, the Interregional public organization “Alliance of Clinical Chemotherapists and Microbiologists”, the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), the public organization “Russian Sepsis Forum”. These recommendations reflect the interdisciplinary consensus opinion on approaches to the diagnosis and antimicrobial therapy of infections caused by polyresistant microorganisms.

Verified
Journal Article
Open access
PDF file
SASergey Avdeev
Sergey Avdeev
Svetlana RachinaSvetlana Rachina
Svetlana Rachina
YBYuliya Belkova
Yuliya Belkova
Roman KozlovRoman Kozlov
Roman Kozlov
AVAnn Versporten
Ann Versporten
OGOn behalf of Russian Global-PPS Project Study Group
On behalf of Russian Global-PPS Project Study Group
The COVID-19 pandemic is a global public health challenge with understudied effects on antimicrobial usage. We aimed to analyze antimicrobial prescribing patterns in COVID-19 patients in Russian multi-field hospitals by means of the Global-PPS Project developed by the University of Antwerp. Out of 999 patients in COVID-19 wards in six hospitals surveyed in 2021, 51.3% received antimicrobials (79% in intensive care, 47.5% in medical wards). Systemic antivirals and antibiotics were prescribed to 31% and 35.1% of patients, respectively, and a combination of both to 14.1% of patients. The top antivirals administered were favipiravir (65%), remdesivir (19.2%), and umifenovir (15.8%); the top antibiotics were ceftriaxone (29.7%), levofloxacin (18%), and cefoperazone/sulbactam (10.4%). The vast majority of antibiotics was prescribed for treatment of pneumonia or COVID-19 infection (59.3% and 25.1%, respectively). Treatment was based on biomarker data in 42.7% of patients but was targeted only in 29.6% (6.7% for antibiotics). The rate of non-compliance with guidelines reached 16.6%. Antimicrobial prescribing patterns varied considerably in COVID-19 wards in Russian hospitals with groundlessly high rates of systemic antibiotics. Antimicrobial usage surveillance and stewardship should be applied to inpatient care during the COVID-19 pandemic.

28 April 2023 in Annals of Critical Care
Verified
Journal Article
Open access
PDF file
АBА. О. Bykov
А. О. Bykov
MSM. P. Suvorova
M. P. Suvorova
DPD. N. Protsenko
D. N. Protsenko
SYSergey V. Yakovlev
Sergey V. Yakovlev
OIO. V. Ignatenko
O. V. Ignatenko
СЯСергей Владимирович Яковлев
Сергей Владимирович Яковлев
INTRODUCTION: Creation of protocols for effective empiric antimicrobial therapy is impossible without the analysis of current antibiotic susceptibility data. OBJECTIVE: Analysis of changes in the etiological significance of the leading pathogens of bacteremia in the ICU (intensive care unit) in the period from 2003 to 2021, and their sensitivity to antibiotics; study of the types of carbapenemases in the most relevant pathogens — Klebsiella pneumoniae and Acinetobacter baumannii. MATERIALS AND METHODS: The analysis included all microorganisms isolated from the blood of patients who were in the medical 12-bed ICU in the emergency hospital of Moscow in the period from 2003 to 2021. Identification of microorganisms and determination of antibiotic sensitivity were carried out with an automatic PHOENIX analyzer and a standardized disco diffusion method. Detection of carbapenemases was carried out by PCR (polymerase chain reaction). RESULTS: In the period from 2003 to 2021, 17 034 blood samples were examined, from which 6372 microorganisms were isolated. During this period, the proportion of Gram-negative microorganisms increased from 21.0 to 52.8 %, mainly due to K. pneumoniae from 1.0 to 24.5 % and A. baumannii from 0 to 9.1 %. The resistance of these microorganisms to carbapenems increased significantly from 2008 to 2021: K. pneumoniae from 2.3 % to 70.3 %, A. baumannii — from 7.5 to 99.5 %. K. pneumoniae produced the following types of carbapenemases: OXA-48 (73.8 %), KPC (6.2 %), NDM 1.5 %, NDM + OXA-48 (15.4 %), KPC + OXA-48 (3.1 %). All A. baumannii strains produced OXA-40 type carbapenemase. OXA-48 carbapenemase producers were resistant to colistin and tigecycline in 14.6 and 44.8 %, and to ceftazidime/avibactam in 4.2 %. CONCLUSIONS: The increased level of antimicrobial resistance in recent years among Gram-negative microorganisms isolated from blood is a very significant problem in the ICU. Most K. pneumoniae strains are characterized as multi-drug resistant, about 10 % of the strains were categorized as extremely-drug resistant (XDR) or pan-drug resistant. All strains of A. baumannii belong to the category of XDR.

12 October 2022 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
ISIgor Sychev
Igor Sychev
LFL. V. Fedina
L. V. Fedina
DGD. A. Gabrielyan
D. A. Gabrielyan
TRT. D. Rastvorova
T. D. Rastvorova
ESE. V. Strigunkova
E. V. Strigunkova
DSDmitry Sychev
Dmitry Sychev
Cardiovascular disease is the most common cause of death in the world. For almost 60 years vitamin K antagonists (VKAs) have been the mainstay of anticoagulant therapy, but in recent years direct oral anticoagulants (DAACs) have become the anticoagulant of choice, as they have many well-known advantages: more predictable anticoagulant effect, no need for dose selection (there is a need for dose adjustment only for renal dysfunction), routine laboratory monitoring of pharmacodynamic effect (except in special clinical situations), less frequency of clinically significant drug interactions compared with warfarin, and less dependence on patient genetic characteristics. The main indications for POAC are: prevention of venous thromboembolism in patients who have undergone endoprosthesis of lower limbs, prevention of stroke and systemic embolism in patients with atrial fibrillation, treatment and prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism. The administration of direct oral anticoagulants (DOACs) has long been considered a major therapeutic advance, mainly because they do not require therapeutic monitoring. Despite this, POACs, like vitamin K antagonists, can still cause major and clinically significant minor bleeding, even when used correctly. Considering that POAC patients are often older and have multiple comorbidities, polypragmasy is widespread. Drug interactions involving POACs are important contributors to the increased risk of bleeding. Awareness of these drug interactions and how to address them is critical to optimizing treatment while reducing the risk of bleeding. This review provides an overview of POAC metabolism, the most common drugs that may interact with POACs, and ways to eliminate these interactions.

13 February 2021 in Antibiot Khimioter = Antibiotics and Chemotherapy
Verified
Journal Article
Closed access
PDF file
SYS. V. Yakovlev
S. V. Yakovlev
MSM. P. Suvorova
M. P. Suvorova
ABA. O. Bykov
A. O. Bykov
SZSergey Vladimirovich Zhuravel
Sergey Vladimirovich Zhuravel
KPK. A. Popugaev
K. A. Popugaev
CЯC. В. Яковлев
C. В. Яковлев
The aim of the study was to evaluate the effectiveness of cefepime/sulbactam in patients with intra-abdominal infection, nosocomial pneumonia (NP) or ventilator-associated pneumonia (VAP) in actual clinical practice. Material and methods. The study was conducted in 14 Russian Clinics from October 2019 to March 2020. Study design: an open-label, prospective, non-comparative, multicenter, observational study. The study included patients who met the inclusion/exclusion criteria and signed a written informed consent. The studied antibiotic: cefepime/sulbactam (Maxictam®-AF). The primary parameter for effectiveness evaluation was the clinical effect after the conclusion of cefepime/sulbactam therapy — recovery/improvement or no effect. Results. The study included 140 patients (average age — 60.8 years) who received at least one dose of cefepime/sulbactam; 37 of them had intraabdominal infection, 72 — NP, and 31 — VAP. Most of the included patients were in the ICU department (82.1%) and their condition was severe: the average APACHE II score was 15.5 points, SOFA — 5.4 points, the Mannheim peritonitis index value in patients with intra-abdominal infection was from 14 to 35 points, with an average of 24.3 points. The majority of patients treated with cefepime/sulbactam (68.6%) had one or more risk factors for multi-resistant pathogens upon hospital or ICU admission. Cefepime/sulbactam was prescribed as the 1st or 2nd line of empirical therapy at a daily dose of 4 g (in 68.3%), 6 g (2.9%) or 8 g (28.8%); most patients were prescribed cefepime/sulbactam in monotherapy (72.3%). The average duration of therapy with cefepime/sulbactam was 9.6±3.5 days. The final assessment of treatment effectiveness was carried out in 132 patients: recovery or improvement was noted in 80.6% of patients with intra-abdominal infection, the effectiveness in NP and VAP was slightly higher — 95.6 and 89.3%. The effect was absent in 5.3% of patients, relapse or superinfection was noted in 3.0 and 1.5%. The majority of patients (81.3%) treated with cefepime/sulbactam were discharged from the hospital. No serious side effects were observed. In patients with a positive effect, age and values of APACHE II were significantly lower (59.58 years and 14.79 points) compared to those with no effect (67.95 years and 18.39 points). A multivariate analysis found that the probability of recovery of patients treated with cefepime/sulbactam did not depend on the diagnosis of infection, ICU admission, the presence of sepsis or septic shock. Conclusion. The multicenter study has established a high clinical efficacy of cefepime/sulbactam in real clinical practice in the treatment of patients with severe intraabdominal infection, nosocomial pneumonia or ventilator-associated pneumonia.

22 December 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
Svetlana RachinaSvetlana Rachina
Svetlana Rachina
LFLudmila V. Fedina
Ludmila V. Fedina
MSMarina V. Sukhorukova
Marina V. Sukhorukova
ISIgor Sychev
Igor Sychev
ELEgor S. Larin
Egor S. Larin
AAAbdulbari A. Alkhlavov
Abdulbari A. Alkhlavov
Nosocomial pneumonia is a healthcare-associated infection with significant consequences for the patient and the healthcare system. The efficacy of treatment significantly depends on the timeliness and adequacy of the antibiotic therapy regimen. The growth of resistance of gram-negative pathogens of nosocomial pneumonia to antimicrobial agents increases the risk of prescribing inadequate empirical therapy, which worsens the results of patient treatment. Identification of risk factors for infection with multidrug-resistant microorganisms, careful local microbiological monitoring with detection of resistance mechanisms, implementation of antimicrobial therapy control strategy and use of rational combinations of antibacterial drugs are of great importance. In addition, the importance of using new drugs with activity against carbapenem-resistant strains, including ceftazidime/aviabactam, must be understood. This review outlines the current data on the etiology, features of diagnosis and antibacterial therapy of nosocomial pneumonia.